Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Osteoporosis 4 Prostatic Neoplasms 3 Breast Neoplasms 3 Vitamin D Deficiency 2 Polycystic Ovary Syndrome 2 Neoplasms 2 Cardiovascular Diseases 2 Vitamin D3 1 Neuroma 1 Melanoma, Cutaneous Malignant 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Locally Advanced Breast Cancer and Large Operable Breast Cancer 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Insulin Resistance 1 Fractures, Bone 1 Colorectal Adenocarcinoma 1

Interventions

Rituximab 66 Cyclophosphamide 46 Vincristine 40 Doxorubicin 40 Prednisone 35 Etoposide 19 Radiotherapy 14 Gemcitabine 13 Peripheral Blood Stem Cell Transplantation 12 Filgrastim 12 Cytarabine 12 Lenalidomide 11 Carmustine 10 VAP-cyclo protocol 9 Prednisolone 9 Oxaliplatin 9 Melphalan 9 Methotrexate 7 Ifosfamide 7 Mitoxantrone 6 Bleomycin 6 polatuzumab vedotin 5 R-CHOP protocol 4 Methylprednisolone 4 Injections 4 Granulocyte Colony-Stimulating Factor 4 Cyclosporine 4 Cisplatin 4 Carboplatin 4 pegfilgrastim 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Large B-Cell, Diffuse × Cholecalciferol × Clear all

NCT04442412 2022-08-26

FIL_PREVID

Fondazione Italiana Linfomi - ETS

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡